Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer

1463.1000 6.30 (0.43%)

NSE Jul 15, 2025 10:32 AM

25.24% Gain from 52W Low

Volume: 26,137

Ipca Laboratories Ltd.

14 Oct 2024, 12:00AM

1463.10

0.43%

At an inflexion point

Buy: Ipca Laboratories Ltd.

Recommendation Target

Motilal Oswal

After three years of earnings deterioration, IPCA is well-poised to deliver strong earnings growth over FY24-27.

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.